Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Dynactin1 depletion leads to neuromuscular synapse instability and functional abnormalities.

Bercier V, Hubbard JM, Fidelin K, Duroure K, Auer TO, Revenu C, Wyart C, Del Bene F.

Mol Neurodegener. 2019 Jul 10;14(1):27. doi: 10.1186/s13024-019-0327-3.

2.

A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.

Sonbol MB, Benkhadra R, Wang Z, Firwana B, Walden DJ, Mody K, Hubbard JM, Murad MH, Ahn DH, Bekaii-Saab T.

Oncologist. 2019 Sep;24(9):1174-1179. doi: 10.1634/theoncologist.2019-0189. Epub 2019 Jun 4.

PMID:
31164455
3.

The Management of Older Adults with Pancreatic Adenocarcinoma.

Ogden JR, Xie H, Ma WW, Hubbard JM.

Geriatrics (Basel). 2018 Nov 26;3(4). pii: E85. doi: 10.3390/geriatrics3040085. Review.

4.

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials.

Duma N, Kothadia SM, Azam TU, Yadav S, Paludo J, Vera Aguilera J, Gonzalez Velez M, Halfdanarson TR, Molina JR, Hubbard JM, Go RS, Mansfield AS, Adjei AA.

Oncologist. 2019 Jan;24(1):96-102. doi: 10.1634/theoncologist.2017-0687. Epub 2018 Nov 9.

PMID:
30413668
5.

Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma.

Kommalapati A, Tella SH, Goyal G, Borad M, Alberts SR, Roberts L, Hubbard JM, Durgin L, Cleary S, Mahipal A.

HPB (Oxford). 2019 Mar;21(3):379-386. doi: 10.1016/j.hpb.2018.08.004. Epub 2018 Sep 25.

PMID:
30266490
6.

Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience.

Jin Z, Sanhueza CT, Johnson B, Nagorney DM, Larson DW, Mara KC, Harmsen WC, Smyrk TC, Grothey A, Hubbard JM.

Oncologist. 2018 Sep;23(9):1083-1091. doi: 10.1634/theoncologist.2017-0289. Epub 2018 Apr 19.

7.

Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years.

Duma N, Vera Aguilera J, Paludo J, Haddox CL, Gonzalez Velez M, Wang Y, Leventakos K, Hubbard JM, Mansfield AS, Go RS, Adjei AA.

J Oncol Pract. 2018 Jan;14(1):e1-e10. doi: 10.1200/JOP.2017.025288. Epub 2017 Nov 3. Review.

PMID:
29099678
8.

Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.

Houts AC, Ogale S, Zafar Y, Hubbard JM, Satram-Hoang S, Sommer N, Walker MS.

J Gastrointest Cancer. 2019 Mar;50(1):16-22. doi: 10.1007/s12029-017-0017-8.

PMID:
29058260
9.

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, Van Cutsem E, Argilés G, Adenis A, Ychou M, Barone C, Bouché O, Peeters M, Humblet Y, Mineur L, Sobrero AF, Hubbard JM, Cremolini C, Prenen H, Tabernero J, Jarraya H, Mazard T, Deguelte-Lardiere S, Papadimitriou K, Van den Eynde M, Pastorino A, Redaelli D, Bencardino K, Funaioli C, Amatu A, Carlo-Stella G, Torri V, Sartore-Bianchi A, Vanzulli A, Siena S.

ESMO Open. 2017 Feb 13;1(6):e000111. doi: 10.1136/esmoopen-2016-000111. eCollection 2016.

10.

Feasibility and Acceptability of a Dignity Therapy/Life Plan Intervention for Patients With Advanced Cancer.

Dose AM, Hubbard JM, Mansfield AS, McCabe PJ, Krecke CA, Sloan JA.

Oncol Nurs Forum. 2017 Sep 1;44(5):E194-E202. doi: 10.1188/17.ONF.E194-E202.

PMID:
28820511
11.

Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.

Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, Frankel W, Collisson E, Koay EJ, Hubbard JM, Leenstra JL, Meyerhardt J, O'Reilly E; Alliance for Clinical Trials on Oncology.

BMC Cancer. 2017 Jul 27;17(1):505. doi: 10.1186/s12885-017-3441-z.

12.

Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.

Hubbard JM, Grothey A.

Drugs. 2017 Jul;77(10):1091-1103. doi: 10.1007/s40265-017-0759-4. Review.

PMID:
28573435
13.

Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.

Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A.

J Clin Oncol. 2017 Aug 10;35(23):2624-2630. doi: 10.1200/JCO.2016.71.4394. Epub 2017 May 9.

14.

Parent-Infant Skin-to-Skin Contact Following Birth: History, Benefits, and Challenges.

Hubbard JM, Gattman KR.

Neonatal Netw. 2017 Mar 1;36(2):89-97. doi: 10.1891/0730-0832.36.2.89. Review.

PMID:
28320495
15.

Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).

Hubbard JM, Mahoney MR, Loui WS, Roberts LR, Smyrk TC, Gatalica Z, Borad M, Kumar S, Alberts SR.

Target Oncol. 2017 Apr;12(2):201-209. doi: 10.1007/s11523-016-0467-0.

16.

Fatigue in Rapsyn-Deficient Zebrafish Reflects Defective Transmitter Release.

Wen H, Hubbard JM, Wang WC, Brehm P.

J Neurosci. 2016 Oct 19;36(42):10870-10882.

17.

Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.

Zhang BY, Jones JC, Briggler AM, Hubbard JM, Kipp BR, Sargent DJ, Dixon JG, Grothey A.

Clin Colorectal Cancer. 2017 Jun;16(2):124-128. doi: 10.1016/j.clcc.2016.09.003. Epub 2016 Sep 17.

PMID:
27726953
18.

Intraspinal Sensory Neurons Provide Powerful Inhibition to Motor Circuits Ensuring Postural Control during Locomotion.

Hubbard JM, Böhm UL, Prendergast A, Tseng PB, Newman M, Stokes C, Wyart C.

Curr Biol. 2016 Nov 7;26(21):2841-2853. doi: 10.1016/j.cub.2016.08.026. Epub 2016 Oct 6.

19.

Optimization of a Neurotoxin to Investigate the Contribution of Excitatory Interneurons to Speed Modulation In Vivo.

Sternberg JR, Severi KE, Fidelin K, Gomez J, Ihara H, Alcheikh Y, Hubbard JM, Kawakami K, Suster M, Wyart C.

Curr Biol. 2016 Sep 12;26(17):2319-28. doi: 10.1016/j.cub.2016.06.037. Epub 2016 Aug 11.

20.

Management of Colorectal Cancer in Older Adults.

Hubbard JM.

Clin Geriatr Med. 2016 Feb;32(1):97-111. doi: 10.1016/j.cger.2015.08.002. Epub 2015 Oct 14. Review.

PMID:
26614863
21.

Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.

Hubbard JM, Kim G, Borad MJ, Johnson E, Qin R, Lensing J, Puttabasavaiah S, Wright J, Erlichman C, Grothey A.

Invest New Drugs. 2016 Feb;34(1):96-103. doi: 10.1007/s10637-015-0308-5. Epub 2015 Nov 18.

22.

Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice.

Pachman DR, Ruddy K, Sangaralingham LR, Grothey A, Shah ND, Beutler AS, Hubbard JM, Loprinzi CL.

J Natl Compr Canc Netw. 2015 Sep;13(9):1097-101.

PMID:
26358793
23.

The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials.

Thanarajasingam G, Hubbard JM, Sloan JA, Grothey A.

J Natl Cancer Inst. 2015 Aug 1;107(10). pii: djv216. doi: 10.1093/jnci/djv216. Print 2015 Oct.

PMID:
26232762
24.

Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer.

Kasi PM, Thanarajasingam G, Finnes HD, Villasboas Bisneto JC, Hubbard JM, Grothey A.

Case Rep Oncol Med. 2015;2015:420159. doi: 10.1155/2015/420159. Epub 2015 May 21.

25.

When less is more: maintenance therapy in colorectal cancer.

Hubbard JM, Grothey A.

Lancet. 2015 May 9;385(9980):1808-10. doi: 10.1016/S0140-6736(14)62350-3. Epub 2015 Apr 7. No abstract available.

PMID:
25862518
26.

Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers.

Kasi PM, Hubbard JM, Grothey A.

Expert Rev Gastroenterol Hepatol. 2015 Mar;9(3):273-6. doi: 10.1586/17474124.2015.1001743. Epub 2015 Jan 12. Review.

PMID:
25579664
27.

Colorectal cancer in 2014: progress in defining first-line and maintenance therapies.

Hubbard JM, Grothey A.

Nat Rev Clin Oncol. 2015 Feb;12(2):73-4. doi: 10.1038/nrclinonc.2014.233. Epub 2015 Jan 6. Review.

PMID:
25560533
28.

Incorporating biomarkers into cancer and aging research.

Hubbard JM, Cohen HJ, Muss HB.

J Clin Oncol. 2014 Aug 20;32(24):2611-6. doi: 10.1200/JCO.2014.55.4261. Epub 2014 Jul 28. Review.

29.

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.

Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR; Alliance for Clinical Trials in Oncology.

J Natl Cancer Inst. 2014 Jun 12;106(7). pii: dju106. doi: 10.1093/jnci/dju106. Print 2014 Jul. Erratum in: J Natl Cancer Inst. 2014 Jul;106(7). doi:10.1093/jnci/dju228.

30.

Incorporating biomarkers of frailty and senescence in cancer therapeutic trials.

Hubbard JM, Jatoi A.

J Gerontol A Biol Sci Med Sci. 2015 Jun;70(6):722-8. doi: 10.1093/gerona/glu046. Epub 2014 Apr 26. Review.

PMID:
24770389
31.

Colorectal cancer: how emerging molecular understanding affects treatment decisions.

Sridharan M, Hubbard JM, Grothey A.

Oncology (Williston Park). 2014 Feb;28(2):110-8. Review.

32.

Physician perspective on incorporation of oncology patient quality-of-life, fatigue, and pain assessment into clinical practice.

Hubbard JM, Grothey AF, McWilliams RR, Buckner JC, Sloan JA.

J Oncol Pract. 2014 Jul;10(4):248-53. doi: 10.1200/JOP.2013.001276. Epub 2014 Mar 25.

33.

The challenge to optimize medical therapy for advanced colorectal cancer.

Hubbard JM, Grothey A.

J Natl Cancer Inst. 2014 Feb;106(2):djt442. doi: 10.1093/jnci/djt442. No abstract available.

PMID:
24511110
34.

Synchronous and asynchronous modes of synaptic transmission utilize different calcium sources.

Wen H, Hubbard JM, Rakela B, Linhoff MW, Mandel G, Brehm P.

Elife. 2013 Dec 24;2:e01206. doi: 10.7554/eLife.01206.

35.

Adolescent and young adult colorectal cancer.

Hubbard JM, Grothey A.

J Natl Compr Canc Netw. 2013 Oct 1;11(10):1219-25. Review.

PMID:
24142823
36.

The pathological phenotypes of human TDP-43 transgenic mouse models are independent of downregulation of mouse Tdp-43.

Xu YF, Prudencio M, Hubbard JM, Tong J, Whitelaw EC, Jansen-West K, Stetler C, Cao X, Song J, Zhang YJ.

PLoS One. 2013 Jul 26;8(7):e69864. doi: 10.1371/journal.pone.0069864. Print 2013.

37.

Alternate dosing of cetuximab for patients with metastatic colorectal cancer.

Hubbard JM, Alberts SR.

Gastrointest Cancer Res. 2013 Mar;6(2):47-55.

38.

Zebrafish calls for reinterpretation for the roles of P/Q calcium channels in neuromuscular transmission.

Wen H, Linhoff MW, Hubbard JM, Nelson NR, Stensland D, Dallman J, Mandel G, Brehm P.

J Neurosci. 2013 Apr 24;33(17):7384-92. doi: 10.1523/JNEUROSCI.5839-12.2013.

39.

Systemic therapy for elderly patients with gastrointestinal cancer.

Hubbard JM, Grothey A, Sargent DJ.

Clin Med Insights Oncol. 2011;5:89-99. doi: 10.4137/CMO.S6983. Epub 2011 Apr 25.

40.

Treatment of liver-limited metastatic colorectal cancer.

Hubbard JM, Alberts SR.

Cancer J. 2010 May-Jun;16(3):235-40. doi: 10.1097/PPO.0b013e3181e075e9. Review.

PMID:
20526102
41.

Current activity guidelines for CABG patients are too restrictive: comparison of the forces exerted on the median sternotomy during a cough vs. lifting activities combined with valsalva maneuver.

Parker R, Adams JL, Ogola G, McBrayer D, Hubbard JM, McCullough TL, Hartman JM, Cleveland T.

Thorac Cardiovasc Surg. 2008 Jun;56(4):190-4. doi: 10.1055/s-2008-1038470.

PMID:
18481235
42.
43.

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE Jr, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP.

Antimicrob Agents Chemother. 2005 Mar;49(3):1127-34.

44.

CaSm antisense gene therapy: a novel approach for the treatment of pancreatic cancer.

Kelley JR, Fraser MM, Hubbard JM, Watson DK, Cole DJ.

Anticancer Res. 2003 May-Jun;23(3A):2007-13. Review.

PMID:
12894573
46.

Computer modeling 16 S ribosomal RNA.

Hubbard JM, Hearst JE.

J Mol Biol. 1991 Oct 5;221(3):889-907.

PMID:
1942035
47.

Predicting the three-dimensional folding of transfer RNA with a computer modeling protocol.

Hubbard JM, Hearst JE.

Biochemistry. 1991 Jun 4;30(22):5458-65.

PMID:
2036414
48.

Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials.

Glasser SP, Clark PI, Lipicky RJ, Hubbard JM, Yusuf S.

JAMA. 1991 Mar 27;265(12):1550-4.

PMID:
1671885
49.

The Hymenoptera venom study. III: Safety of venom immunotherapy.

Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC.

J Allergy Clin Immunol. 1990 Nov;86(5):775-80.

PMID:
2229842
50.

Lack of correlation between plasma 4-hydroxyglutethimide and severity of coma in acute glutethimide poisoning. A case report and brief review of the literature.

Curry SC, Hubbard JM, Gerkin R, Selden B, Ryan PJ, Meinhart R, Hagner D.

Med Toxicol Adverse Drug Exp. 1987 Jul-Aug;2(4):309-16.

PMID:
3626855

Supplemental Content

Loading ...
Support Center